Quantitative Pharmacokinetic/Pharmacodynamic Analyses Suggest That the 129/SVE Mouse Is a Suitable Preclinical Pharmacology Model for Identifying Small-Molecule γ-Secretase Inhibitors
Yasong Lu(Pfizer (United States)), David Riddell(Eli Lilly (United States)), Antonia F. Stepan(Pfizer (United States)), Charles E. Nolan(Pfizer (United States)), Leslie R. Pustilnik(Pfizer (United States)), Chakrapani Subramanyam(Pfizer (United States)), Kevin Atchison(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ashley Robshaw(Pfizer (United States)), Liming Zhang, Stacey L. Becker(Pfizer (United States)), Ivan Efremov(Pfizer (United States)), A.J. Hallgren(Pfizer (United States)), Sarah M. Osgood, Emily Happy Miller
Cited by 24
Related Papers
ApoE Promotes the Proteolytic Degradation of Aβ
|Neuron|2008|869
Application of the Bicyclo[1.1.1]pentane Motif as a Nonclassical Phenyl Ring Bioisostere in the Design of a Potent and Orally Active γ-Secretase Inhibitor
|Journal of Medicinal Chemistry|2012|460
Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease
|Nature Medicine|2020|445
Impact of Apolipoprotein E (ApoE) Polymorphism on Brain ApoE Levels
|Journal of Neuroscience|2008|351
Compartmentalization of β-secretase (Asp2) into low-buoyant density, noncaveolar lipid rafts
|Current Biology|2001|302